Clinical Trials Logo

Colorectal Neoplasms clinical trials

View clinical trials related to Colorectal Neoplasms.

Filter by:

NCT ID: NCT01704703 Completed - Clinical trials for Stage IV Colorectal Cancer

Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques

ULTRA
Start date: October 2012
Phase: Phase 2
Study type: Interventional

Open label Phase II study of FOLFIRI + Panitumumab using ultra-selection technology with next generation high sensitivity genotyping of patients with stage IV colorectal cancer refractory to irinotecan without any mutation on KRAS, PIK3Ca, BRAF and NRAS genes detected with highly sensitive techniques.

NCT ID: NCT01703585 Completed - Breast Cancer Clinical Trials

Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples

Start date: October 4, 2012
Phase:
Study type: Observational

This is a feasibility study to look for genetic alterations in tissue and blood samples that may be useful in determining what treatments may be useful in the patient's cancer care.

NCT ID: NCT01703390 Completed - Clinical trials for Metastatic Colorectal Cancer

Biomarker Directed Treatment in Metastatic Colorectal Cancer

Start date: December 4, 2012
Phase: Phase 2
Study type: Interventional

This pilot study is being mounted to assess whether treatment assignment by ERCC-1 gene expression status suggests better clinical results from historical experience in metastatic colorectal cancer (mCRC). In wild type KRAS mCRC patients treated with either FOLFOX or FOLFIRI in combination with cetuximab the median response rate is approximately 60-65%. Biomarker directed treatment in this study may demonstrate that patients with low ERCC-1 treated with FOLFOX and cetuximab, and those with high ERCC-1 treated with FOLFIRI and cetuximab, will improve response rate to 70-75%. KRAS wild type patients will be treated with 6 cycles of one of the following regimens chosen for optimization based on patient characteristics (primary treatment phase). Patients with ERCC-1 < 1.7 relative gene expression of ERCC-1 over ß-actin (ERCC-1 low) will be assigned to treatment with mFOLFOX6 in combination with Cetuximab. Patients with ERCC-1 gene expression > 1.7 relative gene expression of ERCC-1 over over ß-actin (ERCC-1 high) will be assigned to treatment with FOLFIRI in combination with Cetuximab.

NCT ID: NCT01701310 Completed - Anemia Clinical Trials

IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia

IVICA
Start date: April 2012
Phase: Phase 4
Study type: Interventional

116 eligible patients with confirmed non-metastatic colorectal adenocarcinoma and anemia will be randomized to receive either oral ferrous sulphate (control) or intravenous ferric carboxymaltose (intervention). It is hypothesized that intravenous iron supplementation is more efficacious than oral iron therapy.

NCT ID: NCT01700062 Completed - Clinical trials for Colorectal Neoplasms

Medium Calorie Parenteral Nutrition on Patients With Gastrointestinal Cancer Undergoing Surgery

Start date: April 2007
Phase: Phase 4
Study type: Interventional

aimed at investigating the efficacy, safety, and clinical outcome of Medium-Calorie or standard-calorie total parenteral nutrition (TPN) for patients with gastrointestinal cancer undergoing surgery

NCT ID: NCT01697462 Completed - Colorectal Cancer Clinical Trials

An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer (AXIOM)

Start date: July 2009
Phase: N/A
Study type: Observational

This prospective observational study will evaluate the safety and efficacy of Xeloda (capecitabine) administered in monotherapy in patients with metastatic colorectal cancer. Patients will be followed until disease progression or unacceptable toxicity occurs.

NCT ID: NCT01697449 Completed - Colorectal Cancer Clinical Trials

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (RELEVANT)

Start date: March 2009
Phase: N/A
Study type: Observational

This prospective observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in patients with metastatic colorectal cancer. Data will be collected from patients receiving Avastin in combination with chemotherapy according to registered indication in routine clinical practice.

NCT ID: NCT01696695 Completed - Colorectal Cancer Clinical Trials

AXEL Study: An Observational Study of First-Line Xeloda (Capecitabine) Based Chemotherapy With or Without Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer

Start date: July 2011
Phase: N/A
Study type: Observational

This observational study will evaluate the efficacy and safety of different Xeloda (capecitabine) based chemotherapies, alone or in combination with Avastin (bevacizumab), in first line in patients with metastatic colorectal cancer.

NCT ID: NCT01696630 Completed - Colorectal Cancer Clinical Trials

Xenon Combined With Intraoperative Thoracic Epidural Analgesia

Start date: October 2012
Phase: Phase 2
Study type: Interventional

This is a monocentric study in 2 steps: A safety part to assess the feasibility of using Xenon in association with a thoracic epidural analgesia (TEA) with a sequential recruitment of 3, 6 or 9 patients according to predefined safety rules. The second part will randomly allocated patients (1:1) to receive TEA+Xenon or TEA+Desflurane. 28 patients will be enrolled and followed over 45 days.

NCT ID: NCT01695863 Completed - Colorectal Cancer Clinical Trials

Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep

Start date: February 2012
Phase: Phase 4
Study type: Interventional

This study will be comparing patient satisfaction, efficacy comparing miralax with gatorade versus Movi Prep for outpatient colonoscopy.